期刊文献+

云南地区儿童急性髓细胞白血病(非M3型)临床特征及民族差异研究 被引量:1

Ethnic-specific Clinical Features in Children with Non-M3 Acute Myeloid Leukaemia from Yunnan Province
下载PDF
导出
摘要 背景儿童急性髓细胞白血病(AML)是一种高度异质性疾病,但关于AML患儿民族差异与临床关系的研究鲜有报道。目的分析云南地区AML(非M3型)患儿的临床特征及预后,并探究其民族差异。方法收集2015-01-01至2020-03-01昆明市儿童医院收治的初诊AML(非M3型)患儿为研究对象。收集AML患儿的基线临床资料,包括人口学资料(民族、性别、年龄)、一般资料(白细胞计数、血红蛋白、血小板计数、乳酸脱氢酶、骨髓原始细胞数、FAB分型)、染色体核型结果、基因检测结果。从所有患儿入组后开始随访,截至2020-05-31。记录患儿的治疗方案、危险度及预后情况。结果最终纳入AML(非M3型)患儿72例,随访时间为2~60个月;汉族51例,少数民族21例(彝族5例、回族4例、哈尼族3例、白族2例、苗族2例、壮族1例、佤族1例、布依族1例、蒙古族1例、傣族1例)。少数民族患儿白细胞计数高于汉族(P<0.05)。随访截至2020-05-31,汉族和少数民族患儿诱导治疗第一疗程后完全缓解率、复发率、骨髓移植率比较,差异无统计学意义(P>0.05);少数民族患儿危险度、死亡率高于汉族(P<0.05)。随访截至2020-05-31,绘制汉族和少数民族AML患儿的生存曲线进行比较,汉族AML患儿无事件生存率、总生存率高于少数民族(χ^(2)值分别为8.098、12.547,P值分别为0.004、<0.001)。结论云南地区汉族AML患儿危险度分层、预后优于少数民族,但具体原因尚未明确。 Background Childhood acute myeloid leukaemia(AML)is a higly heterogenous disorder.But its clinical characteristics according to ethic groups have been rarely studied.Objective To explore ethnic-specific clinical characteristics and prognosis of paediatric patients with non-M3 AML from Yunnan province.Methods Paediatric patients with newly diagnosed non-M3 AML were rectuited from Kunming Children's Hospital between January 1,2015 and March 1,2020.Basic baseline clinical data,including demographic characteristics(ethnic group,gender,age),general information(white blood cell count,haemoglobin,platelet count,lactate dehydrogenase,bone marrow blast cell,FAB classification),karyotype,and genetic information were collected.All patients were followed up from enrolment to 2020-05-31,and treatment protocols,risk stratifications,and prognoses were collected.Results Seventy-two cases〔51 cases of Han,21 cases of minorities(5 Yi,4 Hui,3 Hani,2 Bai,2 Miao,1 Zhuang,1 Wa,1 Buyi,1 Mongolian and 1 Dai)〕were enrolled,with a follow-up of 2-60 months.Children of ethnic minorities had higher mean white blood cell count did those of Han(P<0.05).Follow-up analysis showed that compared with children of Han,children of ethnic minorities had higher risk and moratlity(P<0.05),but domonstrated simailar complete remission rate,recurrence rate and bone marrow transplantation rate after the first course of induction therapy(P>0.05).Event-free survival rate and overall survival rate of children of Han were higher than those of children of ethnic minorities(χ^(2)=8.098,P=0.004;χ^(2)=12.547,P<0.001).Conclusion Non-M3 AML children of Han had lower risk and better prognosis than those of ethnic minorities in Yunnan,but the reason has not been identified.
作者 毛晓燕 周燕 刘莉 尹润秀 杨春会 崔婷婷 方春连 蒋鸿超 田新 MAO Xiaoyan;ZHOU Yan;LIU Li;YIN Runxiu;YANG Chunhui;CUI Tingting;FANG Chunlian;JIANG Hongchao;TIAN Xin(Department of Pediatrics,the Affiliated Hospital of Southwest Medical University/Sichuan Clinical Research Center for Birth Defects,Luzhou 646000,China;Kunming Children's Hospital/The Affiliated Children's Hospital of Kunming Medical University/Yunnan Key Laboratory of Children's Major Disease Research,Kunming 650000,China;Kunming Medical University,Kunming 650000,China)
出处 《中国全科医学》 CAS 北大核心 2022年第8期979-983,共5页 Chinese General Practice
基金 国家自然科学基金资助项目(81760032)。
关键词 白血病 髓样 急性 白血病 儿童 人种群 汉族 少数民族 预后 Leukemia,myeloid,acute Leukemia Child Ethnic groups Han nationality Minority groups Prognosis
  • 相关文献

参考文献2

二级参考文献43

  • 1Soley Bayraktar,Ulas Darda Bayraktar,Caio Max Rocha-Lima.Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer[J].World Journal of Gastroenterology,2010,16(6):673-682. 被引量:11
  • 2Pession A, Masetti R, Rizzari C, et al. Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia [J]. Blood, 2013, 122 (2): 170-178.
  • 3Creutzig U, Zimmermann M, Dworzak MN, et al. Development of a curative treatment within the AML-BFM studies [J].Klin Pe- diatr, 2013,225 ( 1 ) : 79-86.
  • 4Creutzig U, Zimmermann M, Bourquin JP, et al. Randomized trial comparing liposomal daunombicin with idarubicin as induc- tion for pediatric acute myeloid leukemia: results from Study AML-BFM 2004[J]. Blood, 2013,122 ( 1 ) : 37-43.
  • 5Cooper TM, Franklin J, Gerbing RB, ct al. AAML03P1, a pilot study of the safety of gemtuznmab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children' s Oncology Group EJ]. Cancer, 2012, 118 ( 3 ) : 761-769.
  • 6Gamis AS, Alonzo TA, Meshinchi S, et al. Gemtuzumab ozo- gamicin in children and adolescents with de novo acute mycloid leukemia improves event~ free survival by reducing relapse risk: results from the randomized phase III Children' s Oncolo- gy Group trial AAML0531 [J]. J Clin Oncol, 2014, 32 (27) : 3021-3032.
  • 7Entz-Werle N, Suciu S, van der Werfften Bosch J, et al. Re- suits of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Chil- dren Leukemia Group report [J]. Leukemia, 2005, 19 (12) : 2072-2081.
  • 8Gibson BE, Webb DK, Howman AJ, et al. Results of a random- ized trial in children with acute myeloid leukaemia: medical re- search council AML12 trial[J]. Br J Haematol, 2011,155(3) : 366-376.
  • 9Abrahamsson J, Forestier E, Heldrup J, et al. Response-guided induction therapy in pediatric acute myeloid leukemia with ex- cellent remission rate [ J ]. J Clin Oncol, 2011,29 (3) : 310-315.
  • 10Tsukimoto I, Tawa A, Horibe K, et ah Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group [J]. J Clin Oncol, 2009,27(24) : 4007-4013.

共引文献11

同被引文献13

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部